Jan 3, 2025 · At SpringWorks, we bring tenacity to work every day because patients need answers now. Our late-stage rare oncology programs have the potential to be best-in-class treatments for patients with devastating diseases.

23 hours ago · As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker appears to have attracted the attention of a biopharma bigwig from o

1 day ago · Springworks' shares jumped as much as 39% on the news on Monday morning, before paring some gains. Merck's German-listed shares were down 1.3%. Springworks, which has a market value of nearly $4 ...

19 hours ago · SpringWorks is developing several treatments for different types of cancers and tumors. Merck KGaA, which bills itself as "the world's oldest pharmaceutical and chemical company," is a separate ...

1 day ago · Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring. One of SpringWorks’ drugs, Ogsiveo, is ...

1 day ago · SpringWorks has a market cap of $3 billion. The Reuters report comes a month after a Betaville alert that SpringWorks ( NASDAQ: SWTX ) was at the center o f renewed takeover speculation.

SpringWorks Therapeutics is advancing a diversified pipeline of targeted oncology programs as both standalone and combination therapies. Our development programs include late-stage rare oncology programs as well as multiple programs addressing highly …

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company that applies a precision medicine approach to developing and delivering life-changing medicines. We do it to help patients suffering from devastating cancers live longer, better lives.

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines to help patients suffering from devastating cancers live longer, better lives.

21 hours ago · Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics regarding a potential acquisition.“Merck also confirms that no legally binding agreement has been entered into.